Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.4M Sell
243,519
-49,235
-17% -$3.28M 0.61% 50
2026
Q1
$18.4M Buy
+292,754
New +$20.4M 0.75% 41
2025
Q3
Sell
-4,844
Closed -$423K 116
2025
Q2
$423K Sell
4,844
-752
-13% -$58.9K 0.06% 100
2025
Q1
$382K Hold
5,596
0.07% 104
2024
Q4
$435K Sell
5,596
-32
-0.6% -$2.37K 0.08% 97
2024
Q3
$377K Hold
5,628
0.07% 98
2024
Q2
$638K Hold
5,628
0.12% 83
2024
Q1
$781K Buy
5,628
+4,844
+618% +$609K 0.14% 75
2023
Q4
$97.3K Sell
784
-47
-6% -$4.8K 0.02% 103
2023
Q3
$77.5K Sell
831
-1,409
-63% -$159K 0.02% 114
2023
Q2
$288K Sell
2,240
-2,438
-52% -$295K 0.05% 113
2023
Q1
$543K Buy
4,678
+2,792
+148% +$313K 0.08% 106
2022
Q4
$214K Sell
1,886
-1,066
-36% -$117K 0.03% 157
2022
Q3
$237K Sell
2,952
-9,032
-75% -$765K 0.04% 143
2022
Q2
$893K Buy
11,984
+10,540
+730% +$962K 0.13% 96
2022
Q1
$184K Hold
1,444
0.02% 161
2021
Q4
$193K Buy
+1,444
New +$207K 0.02% 159
2020
Q4
Sell
-168
Closed -$17K 186
2020
Q3
$17K Buy
+168
New +$17.6K ﹤0.01% 173

Other funds holding DXCM

Mirova's DXCM Position: Q2 2026 in Review

Mirova reduced its DexCom (DXCM) stake by 17% in Q2 2026, selling an estimated $3.28M and leaving 243,519 shares worth $16.4M. The position accounts for 0.61% of the portfolio, ranked #50.

Mirova first reported a position in DXCM in Q3 2020 and has held it in 18 quarters since. The position peaked at $18.4M in Q1 2026. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Mirova held 243,519 shares of DexCom worth $16.4M as of Q2 2026.
  • Mirova sold 49,235 DexCom shares in Q2 2026, an estimated $3.28M.
  • DexCom made up 0.61% of Mirova's portfolio in Q2 2026, its #50 holding.
  • Mirova first reported a position in DexCom in Q3 2020 and has held it in 18 quarters since.
  • Mirova's DexCom position peaked at $18.4M in Q1 2026.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Mirova's 13F filing for Q2 2026, filed 13 Aug 2026.